Previous Article | Next Article 
Journal of Clinical Microbiology, May 2000, p. 1735-1739, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Serologic Diagnosis of Lyme Borreliosis by Using Enzyme-Linked
Immunosorbent Assays with Recombinant Antigens
Louis A.
Magnarelli,1,*
Jacob W.
Ijdo,2
Steven J.
Padula,3
Richard A.
Flavell,4 and
Erol
Fikrig2
Department of Entomology, The Connecticut
Agricultural Experiment Station, New Haven, Connecticut
065041; Section of Rheumatology,
Department of Medicine,2 and Section of
Immunobiology and Howard Hughes Medical
Institute,4 Yale University School of
Medicine, New Haven, Connecticut 06520; and Division of
Rheumatic Diseases, Department of Medicine, University of
Connecticut Health Center, Farmington, Connecticut
060303
Received 19 October 1999/Returned for modification 28 December
1999/Accepted 21 February 2000
 |
ABSTRACT |
Class-specific enzyme-linked immunosorbent assays (ELISAs) with
purified recombinant antigens of Borrelia burgdorferi sensu stricto and Western blot analyses with whole cells of this spirochete were used to test human sera to determine which antigens were diagnostically important. In analyses for immunoglobulin M (IgM) antibodies, 14 (82%) of 17 serum samples from persons who had erythema
migrans reacted positively by an ELISA with one or more recombinant
antigens. There was frequent antibody reactivity to protein 41-G
(p41-G), outer surface protein C (OspC), and OspF antigens. In an ELISA
for IgG antibodies, 13 (87%) of 15 serum samples had antibodies to
recombinant antigens; reactivity to p22, p39, p41-G, OspC, and OspF
antigens was frequent. By both ELISAs, serum specimens positive for
OspB, OspE, and p37 were uncommon. Analyses of sera obtained from
persons who were suspected of having human granulocytic ehrlichiosis
(HGE) but who lacked antibodies to ehrlichiae revealed IgM antibodies
to all recombinant antigens of B. burgdorferi except OspB
and IgG antibodies to all antigens except OspE. Immunoblotting of sera
from the study group of individuals suspected of having HGE reaffirmed
antibody reactivity to multiple antigens of B. burgdorferi.
There was minor cross-reactivity when sera from healthy subjects or
persons who had syphilis, oral infections, or rheumatoid arthritis were
tested by ELISAs with p37, p41-G, OspB, OspC, OspE, and OspF antigens.
Although the results of class-specific ELISAs with recombinant antigens
were comparable to those recorded for assays with whole-cell antigen and for individuals with confirmed clinical diagnoses of Lyme borreliosis, immunoblotting is still advised as an adjunct procedure, particularly when there are low antibody titers by an ELISA.
 |
INTRODUCTION |
For the laboratory diagnosis of Lyme
borreliosis, enzyme-linked immunosorbent assays (ELISAs) are relied on
heavily for initial screening of sera (11, 14, 23).
Immunoblotting methods also are used to detect antibodies to
Borrelia burgdorferi (5, 6, 15, 20, 30, 31),
but extensive application of these procedures can add considerable cost
to diagnoses. Current ELISAs, which contain whole-cell B. burgdorferi sensu lato, can yield false-positive results
(25). Cross-reactivity of treponemal antibodies with flagellin has been reported (2, 25), but nonspecific
reactions also can occur when there are elevated concentrations of
antibodies to other antigens shared among unrelated bacteria
(14), such as Escherichia coli. Furthermore,
antibodies to heat shock proteins, major antigens common to different
bacteria (4), likewise can cause specificity problems. There
is therefore a need to develop more specific ELISAs, without a loss of
sensitivity, to evaluate these methods and to compare the results with
those of immunoblot analyses.
The production and application of highly specific recombinant proteins
(p) of B. burgdorferi, such as outer surface protein C
(OspC), OspE, OspF, p22, p35 (47-kDa fibronectin-binding protein), and
p39 have improved ELISA performance (2, 6, 10, 16, 23, 26, 27,
29). Evaluations of ELISAs with the VlsE antigen are also
encouraging (17, 18). However, the immune responses of
patients infected with B. burgdorferi vary greatly, and
certain key antigens may not always be expressed in hosts or be
recognized immunologically (2). A series of key immunologic
markers of B. burgdorferi infections have been identified by
performing Western blot analyses, and recombinant antigens have been
produced for ELISAs. The purpose of the present study was to further
evaluate the use of recombinant antigens of B. burgdorferi
in class-specific ELISAs to determine which antigens are diagnostically
most important.
 |
MATERIALS AND METHODS |
Study groups.
Human sera that had been stored at
60°C at
the Connecticut Agricultural Experiment Station and used in earlier
investigations (21-25) were reanalyzed by class-specific
ELISAs (21, 23). The first group consisted of 17 serum
samples from 17 patients who had physician-diagnosed erythema migrans
and antibodies to B. burgdorferi whole cells, as determined
by a polyvalent ELISA. These persons, all Connecticut residents, sought
medical attention and gave blood samples prior to antibiotic therapy
between 1 and 5 weeks after the onset of illness. There was no clinical
or serologic evidence of granulocytic ehrlichial infections in these
patients. An additional 17 serum samples from 17 persons who had
antibodies to both B. burgdorferi and the human granulocytic
ehrlichiosis (HGE) agent in polyvalent assays (24) were
included in the study to determine reactivities to specific B. burgdorferi antigens. These patients, also from Connecticut, had
thrombocytopenia or leukopenia and elevated antibody titers to the
NCH-1 strain of the HGE agent. A third study group consisted of 18 serum samples from 18 subjects who were suspected of having HGE
(24) on the basis of thrombocytopenia or leukopenia and who
had immunoglobulins to B. burgdorferi but who lacked
antibodies to granulocytic ehrlichiae. Sera from this group were
selected for immunoblotting to confirm previous ELISA results
(24) and to compare banding patterns with reactions to
recombinant antigens of B. burgdorferi in ELISAs. To further
assess the specificities of class-specific ELISAs with recombinant
B. burgdorferi antigens, sera from individuals with the
following were selected: syphilis (n = 24 serum
specimens), acute necrotizing ulcerative gingivitis or periodontitis
(n = 6), and rheumatoid arthritis (n = 7). The syphilitic sera had antibodies to Treponema
pallidum at concentrations of 1:1,024 or greater, as determined by
a standardized fluorescent-treponemal antibody-absorption test
(25). The final group consisted of 29 serum samples from
healthy subjects (negative controls) who lived in urban or suburban
areas of Connecticut where this disease and ticks are uncommon. Details
on the clinical findings, sources of sera, and results of serologic
testing for antibodies to the HGE agent have been reported elsewhere
(21-25).
Antigens.
B. burgdorferi (strain 2591) whole-cell
antigen and the following recombinant antigens were tested by
class-specific ELISAs: p22, p37, p39, p41-G, OspB, OspC, OspE, and
OspF. Strain 2591 is very closely related to the B31 and N40 strains of
B. burgdorferi; all three of these strains were isolated in
the northeastern United States. Strains from the United States, the
former Soviet Union, and Japan share key immunodominant proteins
(22), and when used as antigens in ELISAs, serologic test
results for human sera were similar. As described earlier (8, 16,
23, 26), all recombinant antigens were cloned and were expressed
as fusion proteins in E. coli at Yale University (p22, p37,
p41-G, OspB, OspE, and OspF) or the University of Connecticut (p39 and
OspC). The p39 antigen was produced from the DNA of strain 2591 after
amplification by PCR methods with primers (upstream primer,
5'-TAGTGGTAAAGGTACTCTT-3'; downstream primer,
5'-TTAAATAAATTCTTTAAGAAAC-3') whose sequences were
based on a previously published sequence (GenBank accession no. L24194)
(28). The purified glutathione S-transferase fusion proteins were produced from either strain 2591 or strain N40 of
B. burgdorferi, isolates of spirochetes from Connecticut and
New York State, respectively. Affinity-purified glutathione transferase
was tested in negative controls with sera, buffers, and other reagents
to check for false-positive reactions in ELISAs.
ELISAs.
Class-specific assays, developed before (21,
23), were used to detect immunoglobulin M (IgM) or IgG
antibodies. The reagents used in tests with whole-cell, p41-G, OspB,
OspC, OspE, and OspF antigens and net optical density (OD) values for
determination of cutoff values for positive serum specimens have been
reported previously (21, 23). In the evaluation of p22, p37,
and p39 antigens, 23 to 29 serum specimens from healthy subjects were analyzed by the ELISAs to determine critical regions for positive results. For serum dilutions of 1:160, 1:320, and 1:640 or greater, net
OD values were highest for the p39 antigen (0.18, 0.16, and 0.11, respectively) compared with those computed for the p22 (0.08, 0.04, and
0.4, respectively) and the p37 (0.04, 0.04, and 0.04, respectively)
antigens in analyses for IgM antibodies. Cutoff values for detection of
IgG antibodies were the same as those calculated for the p22 antigen in
the ELISA for IgM antibody but were higher for the p39 (0.51, 0.33, and
0.22, respectively) and the p37 (0.23, 0.17, and 0.12, respectively)
antigens. In each case, cutoff values were determined by performing
statistical analyses (three standard deviations plus the mean) with the
net absorbance values for the respective data sets. Antigen
concentrations, determined by a commercially available protein assay
(Bio-Rad, Richmond, Calif.), of 5 µg of protein per ml were most
suitable for retrieval of optimal reactivity with positive human sera.
In analyses of test sera, polystyrene plates contained negative and
positive control sera and checks for glutathione transferase, phosphate-buffered saline (PBS) solution, and horseradish
peroxidase-labeled goat anti-human antibodies. Positive control sera,
obtained from subjects who had erythema migrans, were confirmed as
having antibodies to B. burgdorferi by Western blot
analyses. The working dilution of both conjugates, which were
commercially prepared (Kirkegaard & Perry Laboratories, Gaithersburg,
Md.), was 1:10,000. Murine monoclonal antibodies used earlier
(23) and an antiserum available for the p39 recombinant
antigen were included in addition to the immunoblotting-positive human
control sera to verify the reactivities of recombinant antigens in the ELISAs.
Immunoblots.
In general, procedures used previously
(16) were applied to perform Western blot analyses of human
sera. Briefly, B. burgdorferi (strain N40) proteins,
resolved in 12% gels by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, were transferred to nitrocellulose membranes. Human
sera were diluted to 1:100 in PBS solution before testing. The blocking
reagent was PBS solution containing 5% nonfat dry milk. The secondary
antibody (a 1:1,000 dilution of alkaline phosphatase-conjugated goat
anti-human immunoglobulin) and substrates used in color development
were purchased (Kirkegaard & Perry Laboratories).
 |
RESULTS |
In analyses for IgM antibodies, 14 (82%) serum samples from the
patients who had erythema migrans and antibodies to whole-cell B. burgdorferi in an ELISA also tested positive with one or more recombinant antigens (Table 1). The
numbers of serum specimens positive for p41-G, OspC, and OspF antigens
were lower than those recorded positive by an ELISA with whole-cell
antigen, but these recombinant proteins were recognized more frequently
than the p22, p37, p39, OspB, and OspE antigens. All serum samples from 18 subjects who were diagnosed with HGE and who lacked antibodies to
ehrlichiae were positive for IgM antibody to one or more recombinant antigens; the reactivities of the samples for p22, p37, p39, p41-G, OspC, OspE, and OspF antigens were notably more frequent than the
reactivities of the samples from the erythema migrans group. A similar
pattern of IgM antibody reactivity (except for reactivity to OspE) was
noted when sera from patients who had antibodies to the HGE agent and
B. burgdorferi were tested. In tests of reproducibility (i.e., different days of analyses), antibody titers for 30 (77%) of 39 serum samples varied twofold or less, whereas titers for seven and two
serum samples differed by fourfold and eightfold, respectively.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Reactivity of human sera to whole cells and recombinant
antigens of B. burgdorferi in class-specific ELISA for
IgM antibodies
|
|
Patterns of serum reactivity to whole-cell and recombinant antigens of
B. burgdorferi in ELISAs for IgG antibodies were similar to
those observed in analyses for IgM antibodies. Thirteen (87%) of 15 serum samples from persons who had erythema migrans and antibodies to
whole-cell antigens also reacted to one or more recombinant antigens.
The numbers of serum samples with reactivity to the p22, p37, p41-G,
OspE, and OspF antigens for the erythema migrans study group were
comparable to those recorded for both HGE groups (Table
2). However, reactivity to p37 and OspE
remained infrequent. Aside from the results for the p22, OspB, and OspE antigens, the numbers of serum specimens with reactivity to the remaining recombinant antigens for the HGE study groups were
lower in analyses for IgG antibodies than in tests for IgM
antibodies. In both class-specific assays, OspC, OspF, and p41-G were
frequently recognized antigens for subjects with B. burgdorferi infections. Tests on the reproducibility of antibody
titers for 31 serum samples analyzed on different days revealed changes
of twofold or less (78%), fourfold (10%), or eightfold (12%).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Reactivity of human sera to whole cells and recombinant
antigens of B. burgdorferi in class-specific ELISA for
IgG antibodies
|
|
Analyses were performed to assess specificity. Syphilitic sera with
high concentrations of T. pallidum antibodies (1:1024 or
greater) reacted frequently with B. burgdorferi whole-cell antigen in ELISAs for the detection of IgM (Table 1) and IgG antibodies
(Table 2). Aside from this study group, the prevalence of
false-positive reactions with whole-cell antigen was low when sera from
persons who had oral infections or rheumatoid arthritis were tested.
The sera from healthy subjects were negative by both class-specific
ELISAs with whole-cell antigen. The overall frequency of nonspecific
results for the syphilitic sera was low when recombinant antigens were
tested. Similarly, infrequent false-positive reactions were noted by
both class-specific assays when sera from persons who had oral
infections or rheumatoid arthritis were tested with p22, p37, p41-G,
OspC, OspE, and OspF antigens. The reactivities to the p22 and p39
antigens of the sera from the rheumatoid arthritis study group
paralleled those recorded when sera from healthy subjects were tested
by both class-specific ELISAs. Of the total of 27 serum specimens from
healthy subjects with false-positive reactions by screening with
recombinant antigens in both class-specific assays, 9 (33%) had a
titer of 1:160. The antibody titers for the remaining 18 serum
specimens ranged from 1:320 (n = 11) to 1:640
(n = 7). In analyses for IgM antibodies, a titer of
1:160 was recorded for three and two serum specimens tested with OspC and p41-G antigens, respectively. There were no false-positive reactions in analyses with OspB, OspE, and OspF antigens. The prevalence of nonspecific reactions was 2 specimens or less when 29 serum specimens from healthy subjects were tested with p37, p41-G, and
OspC antigens. In tests for IgG antibodies, the numbers of
false-positive specimens were likewise low when p37, OspB, OspC, OspE,
and OspF antigens were screened with 28 serum specimens from healthy
subjects; an antibody titer of 1:160 was recorded for each reaction.
Controls for glutathione transferase, PBS buffers, and enzyme were
negative by all tests.
Western blot analyses of 18 serum specimens from 18 subjects who were
suspected of having HGE but who lacked antibodies to granulocytic
ehrlichiae frequently revealed specific antibodies to two or more key
immunodominant proteins of B. burgdorferi (Fig. 1). The immune responses of the patients
varied. In analyses for IgM antibodies, 14 serum specimens had
antibodies to proteins with molecular masses of about 24 kDa (OspC), 39 kDa, and 41 kDa. Five of these samples also contained antibodies to a
93-kDa peptide. One serum sample had antibodies to the 39- and 41-kDa
proteins, while an immunoblot of another serum specimen showed distinct bands at about 19 kDa (OspE), 24 kDa, and 39 kDa. Two serum specimens had antibodies only to flagellin (41 kDa). In analyses for IgG antibodies, immunoblots showed frequent reactivities to multiple proteins of B. burgdorferi. Thirteen serum specimens had
antibodies to OspC and to the 39- and 41-kDa proteins. Other peptides
often recognized immunologically had molecular masses of about 68 kDa (n = 10 serum specimens) and 37 kDa (n = 5). Less frequent antibody reactivity was noted for 34-kDa
(n = 3) and 93-kDa (n = 2) proteins.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 1.
Representative immunoblots of individual human sera,
obtained from patients who had suspected granulocytic ehrlichiosis in
Connecticut during 1995 and 1996, showing IgM or IgG
antibodies to lysates of B. burgdorferi whole-cell antigen.
Molecular masses are indicated in kilodaltons. Lanes 3 to 5 show
positive reactivities of test sera for IgM antibody, lanes 6 to 9 were
judged to be negative, and lanes 1 and 2 contained negative and
positive control sera, respectively. In analyses of the same sera for
IgG antibodies, lanes 5 and 8 were positive, lanes 3, 4, 6, 7, and 9 were graded as negative, and lanes 1 and 2 contained negative and
positive control sera, respectively.
|
|
The results of the ELISAs and immunoblotting were compared to determine
if reactions to key recombinant antigens in the former tests agreed
with those in the latter test with whole-cell antigen. Class-specific
analyses were conducted with 18 serum specimens from HGE patients who
lacked antibodies to ehrlichiae but who had immunoglobulins to B. burgdorferi at titers of 1:320 to 1:40,960. In tests for IgM
antibodies, results of both assays were in agreement when the OspC
(n = 8 serum specimens), p39 (n = 2),
or p41-G (n = 7) antigen was used separately in an
ELISA. When the findings were discordant, three serum specimens were
positive by an ELISA with OspC antigen and negative by immunoblotting,
whereas seven other serum specimens were negative by an ELISA and
positive by Western blot analysis (i.e., distinct bands for a 24-kDa
protein were visible). Immunoblotting methods were usually more
sensitive than ELISAs when the reactivities to several antigens were
evaluated. For example, 16 and 11 serum samples which were negative for
IgM antibody by an ELISA with p39 and p41-G antigens, respectively, were positive by immunoblotting. In analyses for IgG antibodies, the
findings obtained by both assays were in agreement when an ELISA
contained the OspC (n = 10 serum specimens), p39
(n = 2), or p41-G (n = 8) antigen. Two
serum specimens were positive by an ELISA with OspC but were negative
by immunoblotting, whereas six serum specimens were negative by an
ELISA with OspC but were positive by immunoblotting. In addition, 16 and 10 serum specimens were negative when they were tested by an ELISA
with the p39 or the p41-G antigen, respectively, but distinct bands
were observed for these proteins in immunoblots.
 |
DISCUSSION |
Class-specific ELISAs with recombinant antigens can be used to
confirm clinical diagnoses of Lyme borreliosis during early stages of
infection. However, recombinant antigen-based ELISAs have their
limitations. Of the recombinant antigens evaluated in analyses for IgM
antibodies, OspC, OspF, and p41-G were diagnostically the most
important. This supports earlier work (6, 9, 10, 23, 26, 30,
31), which included analyses of recombinant antigens derived from
different genospecies of B. burgdorferi. The reactivities of
IgM antibody in serum with p22, p37, p39, and OspE, however, were
infrequent and of less help in confirming past or current B. burgdorferi infections. Other investigators have found p37
(12) and p39 (7, 29) to be important markers. With a subsequent expansion of the immune response and production of
IgG antibodies during later stages of illness, p22, p39, and OspF
antigens became more useful in laboratory diagnoses. Antibody reactivities to the p22 and p39 antigens have been found to be important indicators of B. burgdorferi infections (1,
2, 6, 7, 16, 20, 29). Other antigens, such as p35 (47-kDa fibronectin-binding protein) and p93, likewise have been shown to be
important markers for early and late Lyme borreliosis, respectively (2, 5-8, 11, 19, 27). Although highly specific for B. burgdorferi infections, OspA and OspB antigens are usually
recognized during late Lyme borreliosis (2), if at all. In
tick transmission studies, mice produced antibodies to p39 but not to
OspA (13). Furthermore, there is considerable variation in
antibody responses in humans infected with B. burgdorferi.
These findings are probably due to differences in the variable
expression of proteins by spirochetes (2, 6) and host immune
responses. Therefore, a panel of key recombinant antigens should be
tested separately by ELISAs as the first method, and immunoblotting
with whole-cell antigen should be used as an adjunct method. Future
studies should include a thorough evaluation of ELISAs and immunoblots
with mixtures of key recombinant antigens to determine if the
sensitivities and specificities of the assay results are comparable to
or better than those obtained when recombinant antigens are tested separately.
Analyses of 18 serum specimens from patients who had HGE (but who
lacked antibodies to granulocytic ehrlichiae) revealed antibodies to
B. burgdorferi by class-specific ELISAs with recombinant
antigens and in Western blot analyses with whole-cell antigens. In
general, the patterns of reactivity in ELISAs paralleled those noted
for sera from persons who had erythema migrans. The numbers of positive reactions, however, to p22, p37, p39, p41-G, OspC, OspE, and OspF in
tests for IgM antibody were more frequent for both HGE groups than for
the erythema migrans group. With the exception of results for p39,
OspB, and OspC, the numbers of serum specimens positive for IgG
antibodies differed very little among the HGE and erythema migrans
study groups. It is possible that a patient with a current HGE
infection and previous exposure to B. burgdorferi may
produce antibodies to both agents (i.e., polyclonal immune
restimulation). Alternatively, there may be nonspecific polyclonal
activation following a single infection and consequent cross-reactivity
in serologic tests due to immunologic responses to common heat shock proteins or other antigens shared by these unrelated bacteria. In our
experience, cross-reactivity is minimal when homologous and
heterologous antigens of the HGE agent and B. burgdorferi are tested with corresponding antisera (24). We suspect that persons who live in tick-infested areas and who experience multiple tick bites are probably exposed to different pathogens over several weeks or months. Therefore, when HGE, Lyme borreliosis, or human babesiosis is suspected, tests for the other tick-associated illnesses should be conducted.
Minor cross-reactivity was noted in analyses when sera from healthy
subjects were tested with recombinant antigens of B. burgdorferi by ELISAs, but no false-positive reactions were
recorded when whole-cell antigen was used. The latter was probably due
to an overall blocking effect associated with the presence of numerous antigens, including diagnostically irrelevant components of B. burgdorferi, in plate wells. The infrequent false-positive
reactions associated with the p39, OspC, OspE, and OspF antigens have
been reported previously (5, 6, 23), but many of these
reactions occurred at a low serum dilution (1:160). Although tests on
reproducibility show little or no change in antibody titers for the
majority of serum specimens reanalyzed, fourfold or greater differences
in titration endpoints can sometimes occur (20). Moreover,
cross-reactivity with treponemal antibodies is often associated with
shared flagellar antigens (25), but these infections can be
separated from Lyme borreliosis by performing the Venereal Disease
Research Laboratory or fluorescent-treponemal antibody-absorption test.
It is also possible that a small number of persons in the healthy
control group may have had a prior unknown exposure to B. burgdorferi with no clinical evidence of infection. Thus, it is
suggested that Western blot analysis continue to be performed with
sera, particularly those that at low dilutions react with recombinant antigens in ELISAs. High-titer antibody reactions (1:640 or greater) to
p22, p37, p41-G, OspC, OspE, and OspF antigens in ELISAs are likely to
be highly specific.
In general, immunoblotting methods appeared to be more sensitive than
ELISAs. Results of blotting confirmed the ELISA findings reported
earlier (24), and the banding patterns were similar to those
described previously (5, 6). An increased sensitivity of
immunoblotting for IgG antibodies has been reported (6), but
in other laboratories, ELISA results have had sensitivity comparable to
or greater than that of immunoblotting (5). In the present
study, there was agreement in results of both procedures for some sera,
but there were also discordant findings. Moreover, our immunoblotting
results were inconclusive for some sera obtained from persons during
early Lyme borreliosis, when current criteria (3, 6) for a
laboratory diagnosis of Lyme borreliosis were followed. With slow rises
in IgM antibody production, banding patterns can be weak or lacking.
Therefore, whenever possible, multiple serum samples obtained at
intervals of at least 6 weeks or greater should be tested by
immunoblotting and ELISAs to verify seroconversions or to document a
fourfold or greater increase in antibody concentrations.
 |
ACKNOWLEDGMENTS |
We thank Tia Blevins, Manchuan Chen, and Hong Tao for technical assistance.
This work was supported, in part, by grants from the Centers for
Disease Control and Prevention and Emerging Infections Program (grants
CCU-111188-02, CCU-106581, and HR8/CCH113382-01), the National
Institutes of Health (grants PO-1-AI-30548 and AI-49387), the Mathers
Foundation, the Arthritis Foundation, the American Heart Association,
federal Hatch funds administered by the U.S. Department of Agriculture,
and funds from the state of Connecticut (Charles Goodyear Award). We
also acknowledge a private contribution from Phyllis E. Mazik. Jacob W. IJdo is supported by a fellowship from the L. P. Markey Charitable
Trust, and Erol Fikrig is a recipient of a clinical scientist award in
translational research from the Burroughs Wellcome Fund. Richard A. Flavell is an investigator at the Howard Hughes Medical Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Entomology, The Connecticut Agricultural Experiment Station, P.O. Box 1106, New Haven, CT 06504-1106. Phone: (203) 974-8466. Fax: (203) 974-8502. E-mail:
louis.magnarelli{at}po.state.ct.us.
 |
REFERENCES |
| 1.
|
Aguero-Rosenfeld, M. E.,
J. Nowakowski,
D. F. McKenna,
C. A. Carbonaro, and G. P. Wormser.
1993.
Serodiagnosis in early Lyme disease.
J. Clin. Microbiol.
31:3090-3095[Abstract/Free Full Text].
|
| 2.
|
Akin, E.,
G. L. McHugh,
R. A. Flavell,
E. Fikrig, and A. C. Steere.
1999.
The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to p35 correlates with mild and brief arthritis.
Infect. Immun.
67:173-181[Abstract/Free Full Text].
|
| 3.
|
Association of State and Territorial Public Health Laboratory Directors and the Centers for Disease Control and Prevention.
1995.
Recommendations, p. 1-7.
In
Proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease. Association of State and Territorial Public Health Laboratory Directors, Washington, D.C.
|
| 4.
|
Carreiro, M. M.,
D. C. Laux, and D. R. Nelson.
1990.
Characterization of the heat shock response and identification of heat shock protein antigens of Borrelia burgdorferi.
Infect. Immun.
58:2186-2191[Abstract/Free Full Text].
|
| 5.
|
Dressler, F.,
J. A. Whalen,
B. N. Reinhardt, and A. C. Steere.
1993.
Western blotting in the serodiagnosis of Lyme disease.
J. Infect. Dis.
167:392-400[Medline].
|
| 6.
|
Engstrom, S. M.,
E. Shoop, and R. C. Johnson.
1995.
Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.
J. Clin. Microbiol.
33:419-427[Abstract].
|
| 7.
|
Fawcett, P. T.,
C. Rose,
K. M. Gibney,
C. A. Chase,
B. Kiehl, and R. A. Doughty.
1993.
Detection of antibodies to the recombinant p39 protein of Borrelia burgdorferi using enzyme immunoassay and immunoblotting.
J. Rheum.
20:734-738[Medline].
|
| 8.
|
Fikrig, E.,
S. W. Barthold,
W. Sun,
W. Feng,
S. R. Telford III, and R. A. Flavell.
1997.
Borrelia burgdorferi p35 and p37 proteins, expressed in vivo, elicit protective immunity.
Immunity
6:531-539[CrossRef][Medline].
|
| 9.
|
Fung, B. P.,
G. L. McHugh,
J. M. Leong, and A. C. Steere.
1994.
Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection.
Infect. Immun.
62:3213-3221[Abstract/Free Full Text].
|
| 10.
|
Gerber, M. A.,
E. D. Shapiro,
G. L. Bell,
A. Sampieri, and S. J. Padula.
1995.
Recombinant outer surface protein C ELISA for the diagnosis of early Lyme disease.
J. Infect. Dis.
171:724-727[Medline].
|
| 11.
|
Gilmore, R. D., Jr.,
K. J. Kappel, and B. J. B. Johnson.
1997.
Molecular characterization of a 35-kilodalton protein of Borrelia burgdorferi, an antigen of diagnostic importance in early Lyme disease.
J. Clin. Microbiol.
35:86-91[Abstract].
|
| 12.
|
Gilmore, R. D., Jr.,
R. L. Murphree,
A. M. James,
S. A. Sullivan, and B. J. B. Johnson.
1999.
The Borrelia burgdorferi 37-kilodalton immunoblot band (P37) used in serodiagnosis of early Lyme disease is the flaA gene product.
J. Clin. Microbiol.
37:548-552[Abstract/Free Full Text].
|
| 13.
|
Golde, W. T.,
K. J. Kappel,
G. Dequesne,
C. Feron,
D. Plainchamp,
C. Capiau, and Y. Lobet.
1994.
Tick transmission of Borrelia burgdorferi to inbred strains of mice induces an antibody response to P39 but not to outer surface protein A.
Infect. Immun.
62:2625-2627[Abstract/Free Full Text].
|
| 14.
|
Hansen, K.,
P. Hindersson, and N. S. Pedersen.
1988.
Measurement of antibodies to the Borrelia burgdorferi flagellum improves serodiagnosis in Lyme disease.
J. Clin. Microbiol.
26:338-346[Abstract/Free Full Text].
|
| 15.
|
Karlsson, M.,
I. Mollegard,
G. Steirnstedt,
M. A. Henriksson, and B. Wretlind.
1988.
Characterization of antibody response in patients with Borrelia meningitis.
Serodiagn. Immunother. Infect. Dis.
2:375-386.
|
| 16.
|
Lam, T. T.,
T.-P. K. Nguyen,
R. R. Montgomery,
F. S. Kantor,
E. Fikrig, and R. A. Flavell.
1994.
Outer surface proteins E and F of Borrelia burgdorferi, the agent of Lyme disease.
Infect. Immun.
62:290-298[Abstract/Free Full Text].
|
| 17.
|
Lawrenz, M. B.,
J. M. Hardham,
R. T. Owens,
J. Nowakowski,
A. C. Steere,
G. P. Wormser, and S. J. Norris.
1999.
Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi.
J. Clin. Microbiol.
37:3997-4004[Abstract/Free Full Text].
|
| 18.
|
Liang, F. T.,
A. C. Steere,
A. R. Marques,
B. J. B. Johnson,
J. N. Miller, and M. T. Philipp.
1999.
Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE.
J. Clin. Microbiol.
37:3990-3996[Abstract/Free Full Text].
|
| 19.
|
Luft, B. J.,
S. Mudri,
W. Jiang,
R. J. Dattwyler,
P. D. Gorevic,
T. Fisher,
P. Munoz,
J. J. Dunn, and W. H. Schubach.
1992.
The 93-kilodalton protein of Borrelia burgdorferi: an immunodominant protoplasmic cylinder antigen.
Infect. Immun.
60:4309-4321[Abstract/Free Full Text].
|
| 20.
|
Ma, B.,
B. Christen,
D. Leung, and C. Vigo-Pelfrey.
1992.
Serodiagnosis of Lyme borreliosis by Western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi.
J. Clin. Microbiol.
30:370-376[Abstract/Free Full Text].
|
| 21.
|
Magnarelli, L. A., and J. F. Anderson.
1988.
Enzyme-linked immunosorbent assays for the detection of class-specific immunoglobulins to Borrelia burgdorferi.
Am. J. Epidemiol.
127:818-825[Abstract/Free Full Text].
|
| 22.
|
Magnarelli, L. A.,
J. F. Anderson,
R. C. Johnson,
R. B. Nadelman, and G. P. Wormser.
1994.
Comparison of different strains of Borrelia burgdorferi sensu lato used as antigens in enzyme-linked immunosorbent assays.
J. Clin. Microbiol.
32:1154-1158[Abstract/Free Full Text].
|
| 23.
|
Magnarelli, L. A.,
E. Fikrig,
S. J. Padula,
J. F. Anderson, and R. A. Flavell.
1996.
Use of recombinant antigens of Borrelia burgdorferi in serologic tests for diagnosis of Lyme borreliosis.
J. Clin. Microbiol.
34:237-240[Abstract].
|
| 24.
|
Magnarelli, L. A.,
J. W. IJdo,
J. F. Anderson,
S. J. Padula,
R. A. Flavell, and E. Fikrig.
1998.
Human exposure to a granulocytic Ehrlichia and other tick-borne agents in Connecticut.
J. Clin. Microbiol.
36:2823-2827[Abstract/Free Full Text].
|
| 25.
|
Magnarelli, L. A.,
J. N. Miller,
J. F. Anderson, and G. R. Riviere.
1990.
Cross-reactivity of nonspecific treponemal antibody in serologic tests for Lyme disease.
J. Clin. Microbiol.
28:1276-1279[Abstract/Free Full Text].
|
| 26.
|
Padula, S. J.,
F. Dias,
A. Sampieri,
R. B. Craven, and R. W. Ryan.
1994.
Use of recombinant OspC from Borrelia burgdorferi for serodiagnosis of early Lyme disease.
J. Clin. Microbiol.
32:1733-1738[Abstract/Free Full Text].
|
| 27.
|
Probert, W. S., and B. J. B. Johnson.
1998.
Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31.
Mol. Microbiol.
30:1003-1015[CrossRef][Medline].
|
| 28.
|
Simpson, W. J.,
W. Cieplak,
M. E. Schrumpf,
A. G. Barbour, and T. G. Schwan.
1994.
Nucleotide sequence and analysis of the gene in Borrelia burgdorferi encoding the immunogenic P39 antigen.
FEMS Microbiol. Lett.
119:381-388[CrossRef][Medline].
|
| 29.
|
Simpson, W. J.,
M. E. Schrumpf, and T. G. Schwan.
1990.
Reactivity of human Lyme borreliosis sera with a 39-kilodalton antigen specific to Borrelia burgdorferi.
J. Clin. Microbiol.
28:1329-1337[Abstract/Free Full Text].
|
| 30.
|
Wilske, B.,
V. Fingerle,
V. Preac-Mursic,
S. Jouris-Heipke,
A. Hofmann,
H. Loy,
H.-W. Pfister,
D. Rossler, and E. Soutschek.
1994.
Immunoblot using recombinant antigens derived from different genospecies of Borrelia burgdorferi sensu lato.
Med. Microbiol. Immunol.
183:43-59[Medline].
|
| 31.
|
Wilske, B.,
G. Schierz,
V. Preac-Mursic,
K. Von Busch,
R. Kuhbeck,
H.-W. Pfister, and K. Einhaupl.
1986.
Intrathecal production of specific antibodies against Borrelia burgdorferi in patients with lymphocytic meningoradiculitis (Bannwarth's syndrome).
J. Infect. Dis.
153:304-314[Medline].
|
Journal of Clinical Microbiology, May 2000, p. 1735-1739, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jobe, D. A., Lovrich, S. D., Asp, K. E., Mathiason, M. A., Albrecht, S. E., Schell, R. F., Callister, S. M.
(2008). Significantly Improved Accuracy of Diagnosis of Early Lyme Disease by Peptide Enzyme-Linked Immunosorbent Assay Based on the Borreliacidal Antibody Epitope of Borrelia burgdorferi OspC. CVI
15: 981-985
[Abstract]
[Full Text]
-
Vojdani, A., Hebroni, F., Raphael, Y., Erde, J., Raxlen, B.
(2007). Novel Diagnosis of Lyme Disease: Potential for CAM Intervention. Evid Based Complement Alternat Med
0: nem138v1-nem138
[Abstract]
[Full Text]
-
Croda, J., Ramos, J. G. R., Matsunaga, J., Queiroz, A., Homma, A., Riley, L. W., Haake, D. A., Reis, M. G., Ko, A. I.
(2007). Leptospira Immunoglobulin-Like Proteins as a Serodiagnostic Marker for Acute Leptospirosis. J. Clin. Microbiol.
45: 1528-1534
[Abstract]
[Full Text]
-
Lahdenne, P., Sarvas, H., Kajanus, R., Eholuoto, M., Sillanpaa, H., Seppala, I.
(2006). Antigenicity of borrelial protein BBK32 fragments in early Lyme borreliosis.. J Med Microbiol
55: 1499-1504
[Abstract]
[Full Text]
-
Mueller, M., Bunk, S., Diterich, I., Weichel, M., Rauter, C., Hassler, D., Hermann, C., Crameri, R., Hartung, T.
(2006). Identification of Borrelia burgdorferi Ribosomal Protein L25 by the Phage Surface Display Method and Evaluation of the Protein's Value for Serodiagnosis.. J. Clin. Microbiol.
44: 3778-3780
[Abstract]
[Full Text]
-
Marangoni, A., Sambri, V., Accardo, S., Cavrini, F., Mondardini, V., Moroni, A., Storni, E., Cevenini, R.
(2006). A Decrease in the Immunoglobulin G Antibody Response against the VlsE Protein of Borrelia burgdorferi Sensu Lato Correlates with the Resolution of Clinical Signs in Antibiotic-Treated Patients with Early Lyme Disease. CVI
13: 525-529
[Abstract]
[Full Text]
-
Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., Wormser, G. P.
(2005). Diagnosis of Lyme Borreliosis. Clin. Microbiol. Rev.
18: 484-509
[Abstract]
[Full Text]
-
Ramamoorthy, R., McClain, N. A., Gautam, A., Scholl-Meeker, D.
(2005). Expression of the bmpB Gene of Borrelia burgdorferi Is Modulated by Two Distinct Transcription Termination Events. J. Bacteriol.
187: 2592-2600
[Abstract]
[Full Text]
-
Marangoni, A., Sparacino, M., Cavrini, F., Storni, E., Mondardini, V., Sambri, V., Cevenini, R.
(2005). Comparative evaluation of three different ELISA methods for the diagnosis of early culture-confirmed Lyme disease in Italy. J Med Microbiol
54: 361-367
[Abstract]
[Full Text]
-
Magnarelli, L. A., IJdo, J. W., Ramakrishnan, U., Henderson, D. W., Stafford, K. C. III, Fikrig, E.
(2004). USE OF RECOMBINANT ANTIGENS OF BORRELIA BURGDORFERI AND ANAPLASMA PHAGOCYTOPHILUM IN ENZYME-LINKED IMMUNOSORBENT ASSAYS TO DETECT ANTIBODIES IN WHITE-TAILED DEER. J Wildl Dis
40: 249-258
[Abstract]
[Full Text]
-
Fikrig, E., Coyle, P. K., Schutzer, S. E., Chen, M., Deng, Z., Flavell, R. A.
(2004). Preferential Presence of Decorin-Binding Protein B (BBA25) and BBA50 Antibodies in Cerebrospinal Fluid of Patients with Neurologic Lyme Disease. J. Clin. Microbiol.
42: 1243-1246
[Abstract]
[Full Text]
-
Priya, C. G., Bhavani, K., Rathinam, S. R., Muthukkaruppan, V. R.
(2003). Identification and evaluation of LPS antigen for serodiagnosis of uveitis associated with leptospirosis. J Med Microbiol
52: 667-673
[Abstract]
[Full Text]
-
Metts, M. S., McDowell, J. V., Theisen, M., Hansen, P. R., Marconi, R. T.
(2003). Analysis of the OspE Determinants Involved in Binding of Factor H and OspE-Targeting Antibodies Elicited during Borreliaburgdorferi Infection in Mice. Infect. Immun.
71: 3587-3596
[Abstract]
[Full Text]
-
Jespersen, D. J., Smith, T. F., Rosenblatt, J. E., Cockerill III, F. R.
(2002). Comparison of the Borrelia DotBlot G, MarDx, and VIDAS Enzyme Immunoassays for Detecting Immunoglobulin G Antibodies to Borrelia burgdorferi in Human Serum. J. Clin. Microbiol.
40: 4782-4784
[Abstract]
[Full Text]
-
Pachner, A. R., Dail, D., Li, L., Gurey, L., Feng, S., Hodzic, E., Barthold, S.
(2002). Humoral Immune Response Associated with Lyme Borreliosis in Nonhuman Primates: Analysis by Immunoblotting and Enzyme-Linked Immunosorbent Assay with Sonicates or Recombinant Proteins. CVI
9: 1348-1355
[Abstract]
[Full Text]
-
Hefty, P. S., Brooks, C. S., Jett, A. M., White, G. L., Wikel, S. K., Kennedy, R. C., Akins, D. R.
(2002). OspE-Related, OspF-Related, and Elp Lipoproteins Are Immunogenic in Baboons Experimentally Infected with Borrelia burgdorferi and in Human Lyme Disease Patients. J. Clin. Microbiol.
40: 4256-4265
[Abstract]
[Full Text]
-
PANELIUS, J., LAHDENNE, P., HEIKKILA, T., PELTOMAA, M., OKSI, J., SEPPALA, I.
(2002). Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii in the serodiagnosis of Lyme borreliosis. J Med Microbiol
51: 731-739
[Abstract]
[Full Text]
-
HEIKKILA, T., SEPPALA, I., SAXEN, H., PANELIUS, J., PELTOMAA, M., HUPPERTZ, H.-I., LAHDENNE, P.
(2002). Cloning of the gene encoding the decorin-binding protein B (DbpB) in Borrelia burgdorferi sensu lato and characterisation of the antibody responses to DbpB in Lyme borreliosis. J Med Microbiol
51: 641-648
[Abstract]
[Full Text]
-
MAGNARELLI, L. A., LAWRENZ, M., NORRIS, S. J., FIKRIG, E.
(2002). Comparative reactivity of human sera to recombinant VlsE and other Borrelia burgdorferi antigens in class-specific enzyme-linked immunosorbent assays for Lyme borreliosis. J Med Microbiol
51: 649-655
[Abstract]
[Full Text]
-
Heikkila, T., Seppala, I., Saxen, H., Panelius, J., Peltomaa, M., Julin, T., Carlsson, S.-A., Lahdenne, P.
(2002). Recombinant BBK32 Protein in Serodiagnosis of Early and Late Lyme Borreliosis. J. Clin. Microbiol.
40: 1174-1180
[Abstract]
[Full Text]
-
Heikkila, T., Seppala, I., Saxen, H., Panelius, J., Yrjanainen, H., Lahdenne, P.
(2002). Species-Specific Serodiagnosis of Lyme Arthritis and Neuroborreliosis Due to Borrelia burgdorferi Sensu Stricto, B. afzelii, and B. garinii by Using Decorin Binding Protein A. J. Clin. Microbiol.
40: 453-460
[Abstract]
[Full Text]
-
Gomes-Solecki, M. J. C., Wormser, G. P., Schriefer, M., Neuman, G., Hannafey, L., Glass, J. D., Dattwyler, R. J.
(2002). Recombinant Assay for Serodiagnosis of Lyme Disease Regardless of OspA Vaccination Status. J. Clin. Microbiol.
40: 193-197
[Abstract]
[Full Text]
-
Panelius, J., Lahdenne, P., Saxen, H., Heikkila, T., Seppala, I.
(2001). Recombinant Flagellin A Proteins from Borrelia burgdorferi Sensu Stricto, B. afzelii, and B. garinii in Serodiagnosis of Lyme Borreliosis. J. Clin. Microbiol.
39: 4013-4019
[Abstract]
[Full Text]
-
Flannery, B., Costa, D., Carvalho, F. P., Guerreiro, H., Matsunaga, J., Da Silva, E. D., Ferreira, A. G. P., Riley, L. W., Reis, M. G., Haake, D. A., Ko, A. I.
(2001). Evaluation of Recombinant Leptospira Antigen-Based Enzyme-Linked Immunosorbent Assays for the Serodiagnosis of Leptospirosis. J. Clin. Microbiol.
39: 3303-3310
[Abstract]
[Full Text]